FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2556509969> ?p ?o ?g. }

• W2556509969 abstract "Abstract Introduction: DLBCL is the more common non Hodgkin lymphoma. This is an aggressive lymphoma that is treated with a standard chemotherapy regimen: R-CHOP. In the last years attempts have been done to improve the outcome both increasing dose-density (CHOP14) or intensity (CHOEP, ACVBP, autologous stem cell transplantation) without obtaining benefit in terms of survival. This has allowed setting R-CHOP administered every 21 days (R-CHOP21) as the standard treatment for DLBCL patients. RDI is an important issue to consider when treating malignancies. Although this a well-known prognostic factor in Hodgkin lymphoma, scarce information has been published in DLBCL. Objective: The purpose of this study is further analyzing the prognostic impact of RDI in two cohorts of DLBCL patients treated with R-CHOP21 or R-CHOP14, to evaluate its differential impact when increasing dose density. Material and methods: All patients diagnosed of DLBCL from January-1999 to June-2013 at University Hospital Son Espases were retrospectively identified from Pathology Department registry to avoid selection bias. Only patients treated with R-CHOP21 or R-CHOP14 +/- radiotherapy were included (N=115). To increase the R-CHOP14 cohort we added also all patients treated with R-CHOP14 in the same time period in two additional hospitals (Hospital Son Llatzer of Palma and Hospital del Mar of Barcelona) identified from their Pharmacy registries to avoid selection bias (N=42). Other regimes, consolidations or maintenance were excluded. Table 1 shows main characteristics of the global series (N=157). RDI represents the ratio of the amount of a drug actually administered to the amount planned for a fixed time period. RDI was calculated as previously described. Briefly, RDI of each drug was obtained followed by an average of RDI in CHOP consisting in the sume of RDI of the 3 drugs divided by 3. Main prognostic factors at diagnosis in DLBCL were obtained, including international prognostic index (IPI) factors. Evaluations were carried out following standard guidelines. Results: Overall response and complete response rates were similar in both groups:86% and 76% for R-CHOP21 and 94% and 74% for R-CHOP14(p=0.17 and p=0.85, respectively). Median follow-up for alive patients was 68 months (4-156). There were no differences between the two cohorts in terms of either OS or PFS (Figure 1). In the R-CHOP21, both a reduction higher than 15% in RDI [RR 7.41 (2.51-21.83); (p<0.001)] and an unfavorable R-IPI [RR 2.99 (1.1-8.16); (p=0.032) were independently associated with a worse OS. For PFS only a reduction higher than 15% in RDI [RR 4.41 (1.77-10.99) (p=0.001) was independently associated to worse PFS. By contrast, in the R-CHOP14 group an unfavourable NCCN-IPI [RR 8.74 (2.23-34.25); (p=0.002)] and the presence of B-symptoms [RR 5.13 (1.98-13.3); p=0.001)] was independently associated to worse OS and having a AA stage III-IV [RR 5.09 (1.14-22.62); p=0.032)] and bulky disease [RR 3.95 (1.46-10.7); p=0.007)] were independently related to worse PFS. RDI reductions did not show any significant impact in OS or PFS in patients treated with R-CHOP14 (Figure 2). Conclusions: Overall in our series there were no differences in terms of response or survival between patients treated with R-CHOP21 or R-CHOP14. A higher rate of RDI reduction was observed in the R-CHOP14 group. However, the impact of RDI reductions on response and survival was only observed in the R-CHOP21 group but not in patients treated with R-CHOP14. We can conclude that R-CHOP21 and R-CHOP14 are equivalent regimens in terms of response and survival only if RDI reductions are avoided. For patients receiving R-CHOP21 we recommend using clinical and support measures in order to avoid RDI reductions. Table 1. Main clinical characteristics of the patients. R-CHOP21 group(n=74) R-CHOP14 group(n=83) P Age (median & range) 65 (25-88) 55 (15-79) 0.005 Sex (M/F) 34 (46%) / 40 (54%) 51 (61%) / 32 (39%) 0.056 ECOG PS > 1 17 (23%) 18 (22%) 0.85 Ann Arbor stage III-IV 40 (54%) 48 (58%) 0.75 B-symptoms 25 (34%) 26 (31%) 0.86 Elevated LDH 33 (46%) 40 (49%) 0.75 > 1 extranodal site 8 (11%) 19 (23%) 0.057 Bulky disease 23 (31%) 34 (41%) 0.24 R-IPI unfavorable 24 (32%) 26 (32%) 1 NCCN-IPI: - Low - Low-intermediate - High-intermediate - High 9 (13%) 27 (39%) 26 (38%) 7 (10%) 17 (21%) 35 (44%) 24 (30%) 4 (5%) 0.31 Elevated Beta-2-microglobulin 32 (49%) 31 (39%) 0.24 Radiotherapy 27 (36%) 27 (32%) 0.62 Figure 1. Figure 1. Figure 2. Figure 2. Disclosures No relevant conflicts of interest to declare." @default.
• W2556509969 created "2016-11-30" @default.
• W2556509969 creator A5003809364 @default.
• W2556509969 creator A5006074198 @default.
• W2556509969 creator A5007139199 @default.
• W2556509969 creator A5010206363 @default.
• W2556509969 creator A5015753706 @default.
• W2556509969 creator A5020183082 @default.
• W2556509969 creator A5020337135 @default.
• W2556509969 creator A5022554263 @default.
• W2556509969 creator A5023255264 @default.
• W2556509969 creator A5034313872 @default.
• W2556509969 creator A5035866456 @default.
• W2556509969 creator A5037263853 @default.
• W2556509969 creator A5050589468 @default.
• W2556509969 creator A5051371304 @default.
• W2556509969 creator A5065241418 @default.
• W2556509969 creator A5067708412 @default.
• W2556509969 creator A5078093996 @default.
• W2556509969 creator A5084240123 @default.
• W2556509969 creator A5086818120 @default.
• W2556509969 date "2014-12-06" @default.
• W2556509969 modified "2023-09-26" @default.
• W2556509969 title "Differential Impact of Relative Dose-Intensity Reductions (DIR) in Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP21 or R-CHOP14" @default.
• W2556509969 doi "https://doi.org/10.1182/blood.v124.21.3073.3073" @default.
• W2556509969 hasPublicationYear "2014" @default.
• W2556509969 type Work @default.
• W2556509969 sameAs 2556509969 @default.
• W2556509969 citedByCount "0" @default.
• W2556509969 crossrefType "journal-article" @default.
• W2556509969 hasAuthorship W2556509969A5003809364 @default.
• W2556509969 hasAuthorship W2556509969A5006074198 @default.
• W2556509969 hasAuthorship W2556509969A5007139199 @default.
• W2556509969 hasAuthorship W2556509969A5010206363 @default.
• W2556509969 hasAuthorship W2556509969A5015753706 @default.
• W2556509969 hasAuthorship W2556509969A5020183082 @default.
• W2556509969 hasAuthorship W2556509969A5020337135 @default.
• W2556509969 hasAuthorship W2556509969A5022554263 @default.
• W2556509969 hasAuthorship W2556509969A5023255264 @default.
• W2556509969 hasAuthorship W2556509969A5034313872 @default.
• W2556509969 hasAuthorship W2556509969A5035866456 @default.
• W2556509969 hasAuthorship W2556509969A5037263853 @default.
• W2556509969 hasAuthorship W2556509969A5050589468 @default.
• W2556509969 hasAuthorship W2556509969A5051371304 @default.
• W2556509969 hasAuthorship W2556509969A5065241418 @default.
• W2556509969 hasAuthorship W2556509969A5067708412 @default.
• W2556509969 hasAuthorship W2556509969A5078093996 @default.
• W2556509969 hasAuthorship W2556509969A5084240123 @default.
• W2556509969 hasAuthorship W2556509969A5086818120 @default.
• W2556509969 hasConcept C126322002 @default.
• W2556509969 hasConcept C143998085 @default.
• W2556509969 hasConcept C2778559949 @default.
• W2556509969 hasConcept C2779050716 @default.
• W2556509969 hasConcept C2779338263 @default.
• W2556509969 hasConcept C2781413609 @default.
• W2556509969 hasConcept C71924100 @default.
• W2556509969 hasConcept C72563966 @default.
• W2556509969 hasConceptScore W2556509969C126322002 @default.
• W2556509969 hasConceptScore W2556509969C143998085 @default.
• W2556509969 hasConceptScore W2556509969C2778559949 @default.
• W2556509969 hasConceptScore W2556509969C2779050716 @default.
• W2556509969 hasConceptScore W2556509969C2779338263 @default.
• W2556509969 hasConceptScore W2556509969C2781413609 @default.
• W2556509969 hasConceptScore W2556509969C71924100 @default.
• W2556509969 hasConceptScore W2556509969C72563966 @default.
• W2556509969 hasLocation W25565099691 @default.
• W2556509969 hasOpenAccess W2556509969 @default.
• W2556509969 hasPrimaryLocation W25565099691 @default.
• W2556509969 hasRelatedWork W1996808463 @default.
• W2556509969 hasRelatedWork W2033338296 @default.
• W2556509969 hasRelatedWork W2064262761 @default.
• W2556509969 hasRelatedWork W2076770812 @default.
• W2556509969 hasRelatedWork W2156198319 @default.
• W2556509969 hasRelatedWork W2396727612 @default.
• W2556509969 hasRelatedWork W2536917247 @default.
• W2556509969 hasRelatedWork W2552593872 @default.
• W2556509969 hasRelatedWork W2554523872 @default.
• W2556509969 hasRelatedWork W2559355069 @default.
• W2556509969 hasRelatedWork W2560837841 @default.
• W2556509969 hasRelatedWork W2567657506 @default.
• W2556509969 hasRelatedWork W2587949965 @default.
• W2556509969 hasRelatedWork W2895403217 @default.
• W2556509969 hasRelatedWork W2953216651 @default.
• W2556509969 hasRelatedWork W2979942928 @default.
• W2556509969 hasRelatedWork W3029170393 @default.
• W2556509969 hasRelatedWork W3031607543 @default.
• W2556509969 hasRelatedWork W3103124792 @default.
• W2556509969 hasRelatedWork W2947449665 @default.
• W2556509969 isParatext "false" @default.
• W2556509969 isRetracted "false" @default.
• W2556509969 magId "2556509969" @default.
• W2556509969 workType "article" @default.